MOE Key Laboratory of Bioinorganic and Synthetic Chemistry, School of Chemistry and Chemical Engineering, Sun Yat-sen University, Guangzhou, People's Republic of China.
Int J Nanomedicine. 2013;8:2101-17. doi: 10.2147/IJN.S42440. Epub 2013 Jun 5.
Targeted delivery of small interfering RNA (siRNA) has been regarded as one of the most important technologies for the development of siRNA therapeutics. However, the need for safe and efficient delivery systems is a barrier to further development of RNA interference therapeutics. In this work, a nontoxic and efficient siRNA carrier delivery system of low molecular weight polyethyleneimine (PEI-600 Da) cross-linked with 2-hydroxypopyl-β-cyclodextrin (HP-β-CD) and folic acid (FA) was synthesized for biomedical application.
The siRNA carrier was prepared using a simple method and characterized by nuclear magnetic resonance and Fourier transform infrared spectroscopy. The siRNA carrier nanoparticles were characterized in terms of morphology, size and zeta potential, stability, efficiency of delivery, and gene silencing efficiency in vitro and in vivo.
The siRNA carrier was synthesized successfully. It showed good siRNA binding capacity and ability to protect siRNA. Further, the toxicity of the carrier measured in vitro and in vivo appeared to be negligible, probably because of degradation of the low molecular weight PEI and HP-β-CD in the cytosol. Flow cytometry and confocal microscopy confirmed that the FA receptor-mediated endocytosis of the FA-HP-β-CD-PEI/siRNA complexes was greater than that of the HP-β-CD-PEI/siRNA complexes in FA receptor-enriched HeLa cells. The FA-HP-β-CD-PEI/siRNA complexes also demonstrated excellent gene silencing efficiency in vitro (in the range of 90%), and reduced vascular endothelial growth factor (VEGF) protein expression in the presence of 20% serum. FA-HP-β-CD-PEI/siRNA complexes administered via tail vein injection resulted in marked inhibition of tumor growth and reduced VEGF protein expression in the tumors.
Our results suggest that the FA-HP-β-CD-PEI complex is a nontoxic and highly efficient gene carrier with the potential to deliver siRNA for cancer gene therapy effectively in vitro and in vivo.
靶向递送小干扰 RNA(siRNA)被认为是开发 siRNA 治疗药物的最重要技术之一。然而,安全有效的递送系统的需求是 RNA 干扰治疗进一步发展的障碍。在这项工作中,我们合成了一种低分子量聚乙烯亚胺(PEI-600Da)与 2-羟丙基-β-环糊精(HP-β-CD)和叶酸(FA)交联的无毒高效 siRNA 载体递药系统,用于生物医学应用。
采用简单的方法制备 siRNA 载体,并通过核磁共振和傅里叶变换红外光谱进行表征。通过形态学、粒径和 Zeta 电位、稳定性、体外和体内递送效率以及基因沉默效率对 siRNA 载体纳米粒进行了表征。
成功合成了 siRNA 载体。它表现出良好的 siRNA 结合能力和保护 siRNA 的能力。此外,载体的体外和体内毒性似乎可以忽略不计,这可能是由于低分子量 PEI 和 HP-β-CD 在细胞质中的降解所致。流式细胞术和共聚焦显微镜证实,FA 受体介导的 FA-HP-β-CD-PEI/siRNA 复合物内吞作用大于 FA 受体丰富的 HeLa 细胞中 HP-β-CD-PEI/siRNA 复合物的内吞作用。FA-HP-β-CD-PEI/siRNA 复合物在体外也表现出优异的基因沉默效率(在 90%的范围内),并在存在 20%血清的情况下降低血管内皮生长因子(VEGF)蛋白表达。通过尾静脉注射给予 FA-HP-β-CD-PEI/siRNA 复合物可显著抑制肿瘤生长,并降低肿瘤中的 VEGF 蛋白表达。
我们的结果表明,FA-HP-β-CD-PEI 复合物是一种无毒且高效的基因载体,具有在体外和体内有效递送 siRNA 用于癌症基因治疗的潜力。